FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023688462> ?p ?o ?g. }

• W2023688462 endingPage "146" @default.
• W2023688462 startingPage "140" @default.
• W2023688462 abstract "Background Our previous study found that silymarin (SM) and its major pure component silibinin (SB) have anti-angiogenic effects via decreased vascular endothelium growth factor (VEGF) secretion of LoVo cells (colon cancer). We designed this consecutive study to evaluate the anti-angiogenic effects of SM/SB in vivo, and on VEGF receptor (VEGFR) gene expression. Materials and methods We used LoVo cells exposed to SM/SB in a modified chicken chorioallantoic membrane assay (CAM) to evaluate anti-angiogenic effects. We used EA.hy 926 cells (endothelial cells) exposed to SM/SB to evaluate the effect on VEGFR-1 (Flt-1) and VEGFR-2 (KDR), with 1-step, real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). Results In CAM, SM/SB showed a dose-dependent decrease on the vascular density index (VDI) induced by LoVo cells, as did thalidomide in a concentration of 10 μg/ml. Adding escalating dosages of VEGF successfully reversed this inhibitory effect. RT-PCR revealed that SB up-regulated Flt-1 mRNA expression of EA.hy 926 cells. SM had a similar trend, although the effect was not statistically significant (P = 0.19). Neither drug effected KDR mRNA expression. Conclusion We conclude that anti-angiogenic effects of SM/SB are associated with the up-regulation of VEGFR-1 (Flt-1) gene expression and that they are good candidates for combination therapy to treat colorectal cancer. Our previous study found that silymarin (SM) and its major pure component silibinin (SB) have anti-angiogenic effects via decreased vascular endothelium growth factor (VEGF) secretion of LoVo cells (colon cancer). We designed this consecutive study to evaluate the anti-angiogenic effects of SM/SB in vivo, and on VEGF receptor (VEGFR) gene expression. We used LoVo cells exposed to SM/SB in a modified chicken chorioallantoic membrane assay (CAM) to evaluate anti-angiogenic effects. We used EA.hy 926 cells (endothelial cells) exposed to SM/SB to evaluate the effect on VEGFR-1 (Flt-1) and VEGFR-2 (KDR), with 1-step, real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). In CAM, SM/SB showed a dose-dependent decrease on the vascular density index (VDI) induced by LoVo cells, as did thalidomide in a concentration of 10 μg/ml. Adding escalating dosages of VEGF successfully reversed this inhibitory effect. RT-PCR revealed that SB up-regulated Flt-1 mRNA expression of EA.hy 926 cells. SM had a similar trend, although the effect was not statistically significant (P = 0.19). Neither drug effected KDR mRNA expression. We conclude that anti-angiogenic effects of SM/SB are associated with the up-regulation of VEGFR-1 (Flt-1) gene expression and that they are good candidates for combination therapy to treat colorectal cancer." @default.
• W2023688462 created "2016-06-24" @default.
• W2023688462 creator A5005245278 @default.
• W2023688462 creator A5016453981 @default.
• W2023688462 creator A5019559177 @default.
• W2023688462 creator A5037487531 @default.
• W2023688462 creator A5059916741 @default.
• W2023688462 creator A5063013939 @default.
• W2023688462 date "2005-09-01" @default.
• W2023688462 modified "2023-10-18" @default.
• W2023688462 title "Silibinin Inhibits Angiogenesis via Flt-1, but not KDR, Receptor Up-Regulation1" @default.
• W2023688462 cites W1587020653 @default.
• W2023688462 cites W1783580437 @default.
• W2023688462 cites W1971973901 @default.
• W2023688462 cites W1974847622 @default.
• W2023688462 cites W1978139448 @default.
• W2023688462 cites W1986559037 @default.
• W2023688462 cites W1998572839 @default.
• W2023688462 cites W2003227142 @default.
• W2023688462 cites W2004017211 @default.
• W2023688462 cites W2010468452 @default.
• W2023688462 cites W2018291504 @default.
• W2023688462 cites W2019809922 @default.
• W2023688462 cites W2020968632 @default.
• W2023688462 cites W2026038921 @default.
• W2023688462 cites W2037548392 @default.
• W2023688462 cites W2038784909 @default.
• W2023688462 cites W2047393168 @default.
• W2023688462 cites W2054621026 @default.
• W2023688462 cites W2063168427 @default.
• W2023688462 cites W2074954985 @default.
• W2023688462 cites W2077129920 @default.
• W2023688462 cites W2084506573 @default.
• W2023688462 cites W2084947524 @default.
• W2023688462 cites W2108738678 @default.
• W2023688462 cites W2141046053 @default.
• W2023688462 cites W2144111899 @default.
• W2023688462 cites W2157769714 @default.
• W2023688462 cites W2161242171 @default.
• W2023688462 cites W4247664461 @default.
• W2023688462 doi "https://doi.org/10.1016/j.jss.2005.04.042" @default.
• W2023688462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15993897" @default.
• W2023688462 hasPublicationYear "2005" @default.
• W2023688462 type Work @default.
• W2023688462 sameAs 2023688462 @default.
• W2023688462 citedByCount "40" @default.
• W2023688462 countsByYear W20236884622012 @default.
• W2023688462 countsByYear W20236884622013 @default.
• W2023688462 countsByYear W20236884622014 @default.
• W2023688462 countsByYear W20236884622016 @default.
• W2023688462 countsByYear W20236884622017 @default.
• W2023688462 countsByYear W20236884622018 @default.
• W2023688462 countsByYear W20236884622020 @default.
• W2023688462 countsByYear W20236884622021 @default.
• W2023688462 countsByYear W20236884622022 @default.
• W2023688462 countsByYear W20236884622023 @default.
• W2023688462 crossrefType "journal-article" @default.
• W2023688462 hasAuthorship W2023688462A5005245278 @default.
• W2023688462 hasAuthorship W2023688462A5016453981 @default.
• W2023688462 hasAuthorship W2023688462A5019559177 @default.
• W2023688462 hasAuthorship W2023688462A5037487531 @default.
• W2023688462 hasAuthorship W2023688462A5059916741 @default.
• W2023688462 hasAuthorship W2023688462A5063013939 @default.
• W2023688462 hasConcept C126322002 @default.
• W2023688462 hasConcept C134018914 @default.
• W2023688462 hasConcept C150903083 @default.
• W2023688462 hasConcept C167734588 @default.
• W2023688462 hasConcept C170493617 @default.
• W2023688462 hasConcept C185592680 @default.
• W2023688462 hasConcept C207001950 @default.
• W2023688462 hasConcept C2777025900 @default.
• W2023688462 hasConcept C2777130413 @default.
• W2023688462 hasConcept C2778271429 @default.
• W2023688462 hasConcept C2780394083 @default.
• W2023688462 hasConcept C502942594 @default.
• W2023688462 hasConcept C71924100 @default.
• W2023688462 hasConcept C86803240 @default.
• W2023688462 hasConcept C97230052 @default.
• W2023688462 hasConcept C98274493 @default.
• W2023688462 hasConceptScore W2023688462C126322002 @default.
• W2023688462 hasConceptScore W2023688462C134018914 @default.
• W2023688462 hasConceptScore W2023688462C150903083 @default.
• W2023688462 hasConceptScore W2023688462C167734588 @default.
• W2023688462 hasConceptScore W2023688462C170493617 @default.
• W2023688462 hasConceptScore W2023688462C185592680 @default.
• W2023688462 hasConceptScore W2023688462C207001950 @default.
• W2023688462 hasConceptScore W2023688462C2777025900 @default.
• W2023688462 hasConceptScore W2023688462C2777130413 @default.
• W2023688462 hasConceptScore W2023688462C2778271429 @default.
• W2023688462 hasConceptScore W2023688462C2780394083 @default.
• W2023688462 hasConceptScore W2023688462C502942594 @default.
• W2023688462 hasConceptScore W2023688462C71924100 @default.
• W2023688462 hasConceptScore W2023688462C86803240 @default.
• W2023688462 hasConceptScore W2023688462C97230052 @default.
• W2023688462 hasConceptScore W2023688462C98274493 @default.
• W2023688462 hasIssue "1" @default.
• W2023688462 hasLocation W20236884621 @default.
• W2023688462 hasLocation W20236884622 @default.

• next